New Resveratrol Derivatives Exhibit Acetylcholinesterase Inhibitory Properties and Decrease Reactive Oxygen Species Production in the SH-SY5Y Human Neuroblastoma Cell Line

MARTINA DONOZO; VALERIA CAVALLARO; CARLOS J. BAIER; ANA PAULA MURRAY

Conferencia; 2nd International Electronic Conference on Biomedicines; 2023

Sci Forum

Alzheimer´s disease (AD) is a multifactorial neurodegenerative disorder. Acetylcholinesterase (AChE) inhibitors constitute a pharmacotherapeutic strategy for AD treatment. Resveratrol have anti-inflammatory, neuroprotective, anticarcinogenic, and antioxidant properties. This study aimed to evaluate the AChE inhibitory properties and the protective role against oxidative stress damage of 5 resveratrol analogs (M1 to M5) in SH-SY5Y cells. The studied compounds were not cytotoxic in a wide range of concentrations. Treatment of SH-SY5Y cells at the AChE´s IC50s concentration (obtained by in vitro enzyme assays) significantly decreased the AChE enzyme activity in live cells. Through the dichlorofluorescein assay, 3 compounds decreased the endog-enous production of reactive oxygen species (ROS). These results demonstrate that, in addition to their action as biologically active AChE inhibitors, some resveratrol derivatives exhibit neuro-protective effects against endogenous ROS production.